Dabomb Protein (6578) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dabomb Protein (6578) has a cash flow conversion efficiency ratio of -0.013x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-13.86 Million ≈ $-436.60K USD) by net assets (NT$1.03 Billion ≈ $32.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dabomb Protein - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Dabomb Protein's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 6578 total liabilities for a breakdown of total debt and financial obligations.
Dabomb Protein Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dabomb Protein ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Display Tech Co. Ltd
KQ:066670
|
0.068x |
|
Culp, Inc. Common Stock
NYSE:CULP
|
-0.022x |
|
INmune Bio Inc
NASDAQ:INMB
|
-0.214x |
|
Werewolf Therapeutics Inc
NASDAQ:HOWL
|
-0.512x |
|
TNR Gold Corp.
V:TNR
|
-1.253x |
|
Westport Fuel Systems Inc
TO:WPRT
|
0.007x |
|
Carelabs Co.Ltd
KQ:263700
|
-0.027x |
|
Nam Hwa Construction Co.Ltd
KQ:091590
|
-0.020x |
Annual Cash Flow Conversion Efficiency for Dabomb Protein (2015–2024)
The table below shows the annual cash flow conversion efficiency of Dabomb Protein from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Dabomb Protein market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.09 Billion ≈ $34.32 Million |
NT$47.55 Million ≈ $1.50 Million |
0.044x | +542.86% |
| 2023-12-31 | NT$958.06 Million ≈ $30.18 Million |
NT$6.51 Million ≈ $204.97K |
0.007x | -74.94% |
| 2022-12-31 | NT$727.20 Million ≈ $22.91 Million |
NT$19.71 Million ≈ $620.85K |
0.027x | +141.29% |
| 2021-12-31 | NT$674.24 Million ≈ $21.24 Million |
NT$-44.25 Million ≈ $-1.39 Million |
-0.066x | -442.83% |
| 2020-12-31 | NT$700.51 Million ≈ $22.07 Million |
NT$13.41 Million ≈ $422.52K |
0.019x | -59.80% |
| 2019-12-31 | NT$698.39 Million ≈ $22.00 Million |
NT$33.26 Million ≈ $1.05 Million |
0.048x | +53.30% |
| 2018-12-31 | NT$710.52 Million ≈ $22.39 Million |
NT$22.07 Million ≈ $695.42K |
0.031x | -55.90% |
| 2017-12-31 | NT$622.77 Million ≈ $19.62 Million |
NT$43.87 Million ≈ $1.38 Million |
0.070x | -26.73% |
| 2016-12-31 | NT$619.77 Million ≈ $19.53 Million |
NT$59.58 Million ≈ $1.88 Million |
0.096x | -59.24% |
| 2015-12-31 | NT$592.64 Million ≈ $18.67 Million |
NT$139.78 Million ≈ $4.40 Million |
0.236x | -- |
About Dabomb Protein
DaBomb Protein Biotech Corp. manufactures and sells hydrolyzed soy protein in Vietnam, the Philippines, South Korea, Taiwan, and Asia. It offers plant protein, including DaBomb-P (Aqua) and DaBomb-P (Livestock); antibiotics alternatives, such as DBT-100 HT and DBT-100 LS; and pet care products comprising Liqui-TIDE bandages. The company was formerly known as DaBomb Protein Corp. and changed its n… Read more